About Verrica Pharmaceuticals Inc.
https://www.verrica.comVerrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States.
CEO
Jayson M. Rieger
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-25 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:8.88M
Value:$70.61M
BLACKROCK INC.
Shares:1.13M
Value:$8.98M
CALIGAN PARTNERS LP
Shares:923.91K
Value:$7.35M
Summary
Showing Top 3 of 15
About Verrica Pharmaceuticals Inc.
https://www.verrica.comVerrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.34M ▲ | $11.61M ▲ | $-274K ▼ | -1.91% ▼ | $-0.03 ▼ | $2M ▼ |
| Q2-2025 | $12.7M ▲ | $10.85M ▼ | $204K ▲ | 1.61% ▲ | $0.02 ▲ | $2.53M ▲ |
| Q1-2025 | $3.44M ▲ | $11.15M ▲ | $-9.74M ▲ | -283.28% ▲ | $-1.03 ▲ | $-7.33M ▲ |
| Q4-2024 | $344K ▲ | $11.13M ▼ | $-16.2M ▲ | -4.71K% ▼ | $-2.41 ▲ | $-13.6M ▲ |
| Q3-2024 | $-1.78M | $18.49M | $-22.86M | 1.28K% | $-4.88 | $-20.14M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $21.1M ▲ | $40.9M ▲ | $57.94M ▲ | $-17.04M ▲ |
| Q2-2025 | $15.4M ▼ | $39.11M ▼ | $56.59M ▼ | $-17.48M ▲ |
| Q1-2025 | $29.59M ▼ | $42.18M ▼ | $60.75M ▼ | $-18.58M ▼ |
| Q4-2024 | $46.33M ▲ | $54.13M ▲ | $63.99M ▼ | $-9.86M ▲ |
| Q3-2024 | $22.96M | $32.93M | $66.98M | $-34.05M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-274K ▼ | $9.69M ▲ | $0 | $-3.98M ▲ | $5.7M ▲ | $9.69M ▲ |
| Q2-2025 | $204K ▲ | $-10.04M ▲ | $0 | $-4.16M ▼ | $-14.2M ▲ | $-10.04M ▲ |
| Q1-2025 | $-9.74M ▲ | $-12.68M ▲ | $0 ▼ | $-4.06M ▼ | $-16.73M ▼ | $-12.68M ▲ |
| Q4-2024 | $-16.2M ▲ | $-16.06M ▼ | $8K ▲ | $39.43M ▲ | $23.37M ▲ | $-16.06M ▼ |
| Q3-2024 | $-22.86M | $-8.56M | $-16K | $-397K | $-8.97M | $-8.57M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Collaboration | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License And Collaboration Revenue | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jayson M. Rieger
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-25 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ARMISTICE CAPITAL, LLC
Shares:8.88M
Value:$70.61M
BLACKROCK INC.
Shares:1.13M
Value:$8.98M
CALIGAN PARTNERS LP
Shares:923.91K
Value:$7.35M
Summary
Showing Top 3 of 15